ReviewCurrent heart failure reports2010
CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.
Review in Current heart failure reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure.Current heart failure reports · 2023Review
- Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications.International journal of molecular sciences · 2019Review
- Pharmacogenomics of the Natriuretic Peptide System in Heart Failure.Current heart failure reports · 2017Review
- A New Chimeric Natriuretic Peptide, CScientific reports · 2017Article
- Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.European heart journal. Cardiovascular pharmacotherapy · 2016Article
- Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.Current heart failure reports · 2015Review
- Natriuretic Peptides and Cardiometabolic Health.Circulation journal : official journal of the Japanese Circulation Society · 2015Review
- Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.Journal of cardiac failure · 2014Article
- Natriuretic peptides in cardiometabolic regulation and disease.Nature reviews. Cardiology · 2014Review
- Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma.Frontiers in molecular neuroscience · 2014Review
- Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway.Journal of cardiovascular translational research · 2013Article
- In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.Pulmonary pharmacology & therapeutics · 2013Article
- In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide.PloS one · 2013Article
- Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma.PloS one · 2013Article
- Management of the cardiorenal syndrome in acute heart failure.Current treatment options in cardiovascular medicine · 2012Article
- Endothelial actions of atrial and B-type natriuretic peptides.British journal of pharmacology · 2012Review
- cGMP becomes a drug target.Naunyn-Schmiedeberg's archives of pharmacology · 2012Review
- Novel therapeutic targets for the treatment of heart failure.Nature reviews. Drug discovery · 2011Review
- Update on the Management of Acute Decompensated Heart Failure.Current treatment options in cardiovascular medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natriuretic peptide (NP) family consists of structurally similar, although physiologically distinct, peptides that play an important role in cardiorenal homeostasis. CD-NP is a novel chimeric natriuretic peptide developed by the Mayo Clinic, in which the 15-amino acid COOH-terminus of dendroaspis NP is fused to C-type NP. CD-NP is a dual activator of NP receptors A and B, and therefore, possesses the strong antiproliferative and antifibrotic properties of C-type NP with the potent natriuretic, diuretic, and aldosterone-inhibiting properties of dendroaspis NP. CD-NP has favorable cardiorenal properties when compared to recombinant B-type NP (nesiritide), including preservation of glomerular filtration rate with minimal blood pressure-lowering effects. Thus, CD-NP has emerged as an appealing novel therapeutic strategy for heart failure. The endogenous NP system, the development rationale for CD-NP, as well as in vitro, animal, and human studies and future directions will be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.